Shandong Xinhua Pharmaceutical Company Limited Class H (HK:0719) has released an update.
Shandong Xinhua Pharmaceutical Company Limited has announced that its abbreviated new drug application (ANDA) for sevelamer carbonate tablets has received approval from the U.S. Food and Drug Administration (FDA). This development positions the company to enter the market with a prescription drug designed to control hyperphosphatemia in adults with chronic kidney disease undergoing dialysis. The tablets, originally developed by Sanofi Genzyme, are already used in over 40 countries, enhancing their market potential.
For further insights into HK:0719 stock, check out TipRanks’ Stock Analysis page.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
